The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance

[1]  A. McBride,et al.  Proteasome inhibitors in the treatment of multiple myeloma , 2013, Expert review of anticancer therapy.

[2]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[3]  M. Butterworth,et al.  Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells , 2010, Haematologica.

[4]  A. Letai,et al.  Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes , 2010, Proceedings of the National Academy of Sciences.

[5]  A. Gartel,et al.  ARC Synergizes with ABT-737 to Induce Apoptosis in Human Cancer Cells , 2010, Molecular Cancer Therapeutics.

[6]  G. Scagliotti,et al.  A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. , 2010, Lung cancer.

[7]  Lidong Zhang,et al.  Open Access Research Characterization of Bortezomib-adapted I-45 Mesothelioma Cells , 2022 .

[8]  Derek W. Yecies,et al.  Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. , 2010, Blood.

[9]  S. Grant,et al.  Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1 , 2009, Molecular and Cellular Biology.

[10]  M. Yaffe,et al.  Exploiting synthetic lethal interactions for targeted cancer therapy , 2009, Cell cycle.

[11]  Tae-Hyoung Kim,et al.  Effects of the BH3‐only protein human Noxa on mitochondrial dynamics , 2009, FEBS letters.

[12]  D. Fennell,et al.  Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. , 2009, American journal of respiratory cell and molecular biology.

[13]  P. Henklein,et al.  The cell-penetrating peptide octa-arginine is a potent inhibitor of proteasome activities. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[14]  M. Giovannini,et al.  Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates , 2009, Cell Death and Differentiation.

[15]  J. Litz,et al.  Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737 , 2009, Molecular Cancer Therapeutics.

[16]  Valerie M. Weaver,et al.  A tense situation: forcing tumour progression , 2009, Nature Reviews Cancer.

[17]  G. Gordon,et al.  mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. , 2008, American journal of respiratory cell and molecular biology.

[18]  Jeffrey R. Morgan,et al.  Mammalian Target of Rapamycin Contributes to the Acquired Apoptotic Resistance of Human Mesothelioma Multicellular Spheroids* , 2008, Journal of Biological Chemistry.

[19]  R. Sposto,et al.  Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. , 2008, Journal of the National Cancer Institute.

[20]  G. Gordon,et al.  Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma , 2008, Cancer Chemotherapy and Pharmacology.

[21]  K. O'Byrne,et al.  Advances in the systemic therapy of malignant pleural mesothelioma , 2008, Nature Clinical Practice Oncology.

[22]  P. Dent,et al.  Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. , 2007, Blood.

[23]  C. Porta,et al.  Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma , 2007, Clinical Cancer Research.

[24]  F. Pampaloni,et al.  The third dimension bridges the gap between cell culture and live tissue , 2007, Nature Reviews Molecular Cell Biology.

[25]  D. Fennell,et al.  BCL-2 family regulation by the 20S proteasome inhibitor bortezomib , 2007, Oncogene.

[26]  Tomomi Gotoh,et al.  ER Stress Triggers Apoptosis by Activating BH3-Only Protein Bim , 2007, Cell.

[27]  W. Hou,et al.  Functional Linkage between NOXA and Bim in Mitochondrial Apoptotic Events* , 2007, Journal of Biological Chemistry.

[28]  R. Bataille,et al.  Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. , 2007, Cancer research.

[29]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[30]  Keiran S. M. Smalley,et al.  Life ins't flat: Taking cancer biology to the next dimension , 2006, In Vitro Cellular & Developmental Biology - Animal.

[31]  M. Soengas,et al.  Proteasome Inhibitor PS-341 Induces Apoptosis in Cisplatin-resistant Squamous Cell Carcinoma Cells by Induction of Noxa* , 2006, Journal of Biological Chemistry.

[32]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[33]  D. Jablons,et al.  A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. , 2005, American journal of respiratory cell and molecular biology.

[34]  S. Lowe,et al.  Intrinsic tumour suppression , 2004, Nature.

[35]  D. Fennell,et al.  Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. , 2004, The Lancet. Oncology.

[36]  F. Khuri,et al.  Novel agents and incremental advances in the treatment of head and neck cancer. , 2004, Seminars in oncology.

[37]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[38]  E. Campo,et al.  The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. , 2006, Blood.

[39]  S. Futaki.  Oligoarginine vectors for intracellular delivery: design and cellular-uptake mechanisms. , 2006, Biopolymers.

[40]  W. Dalton,et al.  The proteasome. , 2004, Seminars in oncology.